A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

NCT02326584 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Myelogenous Leukemia

Interventions

DRUG: Standard dose cytarabine for induction
DRUG: SGN-CD33A
DRUG: Daunorubicin
DRUG: High dose cytarabine for consolidation

Sponsor

Seagen Inc.